Prevention of AKI in high-risk patients
Acutely ill patients in hospital are at increased risk of AKI, particularly if they have risk factors (e.g., chronic kidney disease, diabetes mellitus, heart failure, or advanced age). You should:[3]National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. September 2023 [internet publication].
https://www.nice.org.uk/guidance/ng148
Use early warning scores (e.g., NEWS2) to help identify patients at risk of AKI because their clinical condition is deteriorating or they are at risk of deteriorating.
Ensure patients at risk of AKI who are admitted to hospital have their serum creatinine level monitored, with a system in place to recognise and respond to acute creatinine changes which meet criteria for AKI.[64]National Institute for Health and Care Excellence. Quality statement 2: identifying acute kidney injury in people admitted to hospital. NICE quality standard QS76: acute kidney injury. March 2023 [internet publication].
Ensure a system of urine output monitoring is in place to recognise and respond to oliguria (urine output <0.5 ml/kg/hour)
Seek advice from a pharmacist about optimising medicines and drug dosing for patients with or at risk of AKI.[3]National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. September 2023 [internet publication].
https://www.nice.org.uk/guidance/ng148
Prevention of contrast-induced AKI
Intravenous iodinated contrast has previously been reported to cause contrast-induced AKI (CI-AKI).[5]Sharfuddin AA, Weisbord SD, Palevsky PM, et al. Acute kidney injury. In: Taal MW, Chertow GM, Marsden PA, et al, eds. Brenner and Rector's the kidney. 9th ed. Philadelphia, PA: Saunders; 2012. However, the association has been questioned by large population studies that have failed to demonstrate this risk.[38]Wilhelm-Leen E, Montez-Rath ME, Chertow G. Estimating the risk of radiocontrast-associated nephropathy. J Am Soc Nephrol. 2017 Feb;28(2):653-9.
https://jasn.asnjournals.org/content/28/2/653.long
http://www.ncbi.nlm.nih.gov/pubmed/27688297?tool=bestpractice.com
[39]Brinjikji W, Demchuk AM, Murad MH, et al. Neurons over nephrons: systematic review and meta-analysis of contrast-induced nephropathy in patients with acute stroke. Stroke. 2017 Jul;48(7):1862-8.
https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.117.016771
http://www.ncbi.nlm.nih.gov/pubmed/28583996?tool=bestpractice.com
[40]Ehrmann S, Quartin A, Hobbs BP, et al. Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis. Intensive Care Med. 2017 Jun;43(6):785-94.
http://www.ncbi.nlm.nih.gov/pubmed/28197679?tool=bestpractice.com
The evidence regarding the prevention of CI-AKI is weak, and often conflicting.[65]Barrett BJ, Parfey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006 Jan 26;354(4):379-86.
http://www.ncbi.nlm.nih.gov/pubmed/16436769?tool=bestpractice.com
[66]Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet. 2017 Apr 1;389(10076):1312-22.
http://www.ncbi.nlm.nih.gov/pubmed/28233565?tool=bestpractice.com
The UK National Institute for Health and Care Excellence (NICE) recommends that you:[3]National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. September 2023 [internet publication].
https://www.nice.org.uk/guidance/ng148
Measure kidney function within 3 months of offering iodinated contrast for non-emergency imaging in adults assessed as being at increased risk of kidney injury.
Encourage oral hydration before and after procedures using intravenous iodinated contrast agents in adults at increased risk of CI-AKI (e.g., CKD, diabetes, heart failure, and advanced age [≥75 years]).
Consider intravenous volume expansion only if the patient is particularly high risk (e.g., eGFR less than 30 ml/min/1.73 m2, kidney transplant).
Do not delay emergency imaging to undertake a risk assessment.
In 2023, the UK Royal College of Radiologists and Royal College of Emergency Medicine issued the following joint recommendations in relation to emergency iodinated intravenous contrast CT scans:[67]Royal College of Emergency Medicine; Royal College of Radiologists. Joint advisory statement between Royal College of Radiologists & Royal College Emergency Medicine regarding emergency computed somography scans and the use of intravenous iodinated contrast agents. May 2023 [internet publication].
https://res.cloudinary.com/studio-republic/images/v1685530101/Emergency_CT_Scans_Requiring_IV_Iodinated_Contrast_Agent/Emergency_CT_Scans_Requiring_IV_Iodinated_Contrast_Agent.pdf?_i=AA
Measurement of renal function or administration of intravenous fluid should not be considered prerequisites for emergency imaging.
Age, pre-existing renal disease, diabetes mellitus, or medications such as metformin should not delay emergency scanning.
Discuss patients on renal replacement therapy or with a kidney transplant with the nephrology team before offering iodinated contrast but do not delay emergency imaging.
Drugs evaluated for prevention of CI-AKI include N-acetylcysteine, high-dose statins, probucol, allopurinol, and alprostadil, but benefits remain uncertain and such therapies should not be used routinely.[68]Weisbord SD, Gallagher M, Jneid H, et al; PRESERVE Trial Group. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018 Feb 15;378(7):603-14.
https://www.nejm.org/doi/10.1056/NEJMoa1710933
http://www.ncbi.nlm.nih.gov/pubmed/29130810?tool=bestpractice.com
[69]Guo Z, Liu J, Lei L, et al. Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2020 Oct 16;10(10):e039009.
https://www.doi.org/10.1136/bmjopen-2020-039009
http://www.ncbi.nlm.nih.gov/pubmed/33067289?tool=bestpractice.com
[70]Magner K, Ilin JV, Clark EG, et al. Meta-analytic techniques to assess the association between N-acetylcysteine and acute kidney injury after contrast administration: a systematic review and meta-analysis. JAMA Netw Open. 2022 Jul 1;5(7):e2220671.
http://www.ncbi.nlm.nih.gov/pubmed/35788669?tool=bestpractice.com
[71]Li H, Wang C, Liu C, et al. Efficacy of short-term statin treatment for the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention: a meta-analysis of 21 randomized controlled trials. Am J Cardiovasc Drugs. 2016 Jun;16(3):201-19.
https://www.doi.org/10.1007/s40256-016-0164-5
http://www.ncbi.nlm.nih.gov/pubmed/26899537?tool=bestpractice.com
[72]Xin W, Lin Z, Zhang T, et al. Probucol for the prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography or percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Clin Nephrol. 2019 Jul;92(1):36-43.
https://www.doi.org/10.5414/CN109701
http://www.ncbi.nlm.nih.gov/pubmed/30964433?tool=bestpractice.com
[73]Xin W, Lin Z, Zhang T, et al. Effects of allopurinol pretreatment on the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Clin Nephrol. 2020 Jan;93(1):24-33.
http://www.ncbi.nlm.nih.gov/pubmed/31661061?tool=bestpractice.com
[74]Xu H, Wang H, Zhang C, et al. Efficacy of alprostadil in preventing contrast-induced nephropathy: a systematic review and meta-analysis. Angiology. 2021 Oct;72(9):878-88.
http://www.ncbi.nlm.nih.gov/pubmed/33853365?tool=bestpractice.com
Prevention of perioperative AKI
Identify patient risk factors for AKI prior to surgery, including:
Sepsis
Hypovolaemia
Intraperitoneal surgery
Chronic kidney disease (eGFR <60 ml/min/1.73 m2)
Diabetes
Heart failure
Age ≥65 years
Liver disease
Nephrotoxins (e.g., NSAIDs, aminoglycoside antibiotics such as gentamicin).